Magnitude of hematologic improvement with metformin
| Hematologic parameter . | Number (N) . | Baseline studies median (range) . | Maximum improvement over baseline median (range) . | Maximum percentage improvement over baseline median (range) . |
|---|---|---|---|---|
| Hemoglobin* g/dL | 13 | 11 g/dL (8.4-14.2) | 0.7 g/dL (0-2.3) | 6.2% (0-27.4) |
| Reticulocyte count (cells/µL) | 14 | 60,000 cells/µL (0.02-0.1) | 2,000 cells/µL (0-0.022) | 4.5% (0-91.7) |
| Mean corpuscular volume (fL) | 14 | 105.3 fL (92.1-111.2) | 1.2 fL (0-6.2) | 1.2% (0-5.6) |
| Platelets (cells/µL) | 14 | 53,800 cells/µL (16-78) | 11,500 cells/µL (0-49) | 31.8% (0-87.5) |
| Neutrophils (cells/µL) | 14 | 1,100 cells/µL (0.6-1.6) | 800 cells/µL (0-1.4) | 55.4% (0-166.7) |
| Hematologic parameter . | Number (N) . | Baseline studies median (range) . | Maximum improvement over baseline median (range) . | Maximum percentage improvement over baseline median (range) . |
|---|---|---|---|---|
| Hemoglobin* g/dL | 13 | 11 g/dL (8.4-14.2) | 0.7 g/dL (0-2.3) | 6.2% (0-27.4) |
| Reticulocyte count (cells/µL) | 14 | 60,000 cells/µL (0.02-0.1) | 2,000 cells/µL (0-0.022) | 4.5% (0-91.7) |
| Mean corpuscular volume (fL) | 14 | 105.3 fL (92.1-111.2) | 1.2 fL (0-6.2) | 1.2% (0-5.6) |
| Platelets (cells/µL) | 14 | 53,800 cells/µL (16-78) | 11,500 cells/µL (0-49) | 31.8% (0-87.5) |
| Neutrophils (cells/µL) | 14 | 1,100 cells/µL (0.6-1.6) | 800 cells/µL (0-1.4) | 55.4% (0-166.7) |
The patient who was transfusion dependent for red blood cells at baseline before metformin initiation was not included in this hemoglobin analysis.